202:
approved
Bioverativ's registration statement, with the official separation date of the two companies being pegged at February 2017. In February, Biogen investors received a special dividend of one share of Bioverativ stock for every two shares of Biogen stock held as of January 17. Bioverativ began
326:, both products provided combined revenues of $ 604 million in 2015, and $ 640 million in the first nine months of 2016 (contributing to ~6% of Biogens' total revenue. These products are marketed in the United States, European Union, Japan, Canada and Australia.
615:
343:
482:
645:
625:
620:
507:
650:
610:
605:
347:
574:
486:
194:
its hemophilia drug business (Eloctate and
Alprolix) into a separate public company. In August, Biogen announced they would call the spun off company
640:
522:
559:
545:
199:
464:
420:
371:
630:
344:"Biogen Announces Additional Members of Management Team of Hemophilia Spin-off Company Bioverativ - Biogen Media"
148:
229:
The following is an illustration of the company's major mergers and acquisitions and historical predecessors:
207:
211:
90:
401:
210:
for $ 825 million, strengthening
Bioverativ's pipeline with the acquisition of TNT009 – a treatment for
154:
company that specializes in the discovery, development, and delivery of therapies for the treatment of
439:
191:
546:"Coming soon to the Nasdaq: Biogen's hemophilia spinoff, Bioverativ - Boston Business Journal"
635:
465:"Amid takeover chatter, Biogen introduces hemophilia spinoff Bioverativ - FiercePharma"
198:
to show heritage with Biogen, and would be spun off in early 2017. On
December 22, the
117:
483:"Biogen Announces Bioverativ as Name of New Hemophilia-Focused Company - Biogen Media"
599:
151:
53:
36:
508:"Biogen (BIIB) Approves Separation of Bioverativ (BIVV); Declares Special Dividend"
171:
155:
174:. The company traded on the NASDAQ exchange under the ticker symbol BIVV until
28:
163:
323:
319:
159:
573:
Hirschler, Ben; Kar-Gupta, Sudip; Erman, Michael (January 22, 2018).
527:
279:
218:
187:
175:
167:
122:
76:
42:
575:"Biotech M&A takes off as Sanofi and Celgene spend $ 20 billion"
440:"Biogen to spin off hemophilia drug business into a public company"
221:
announced that it would acquire the business, for $ 11.6 billion.
616:
Multinational companies headquartered in the United States
408:(67). Net Resources International. January 22, 2018.
206:
In May 2017, the company announced it would acquire
133:
560:"Bioverativ to Acquire True North for up to $ 825M"
128:
116:
106:
98:
83:
59:
49:
34:
24:
540:
538:
646:Pharmaceutical companies disestablished in 2018
523:"Biotech Giant Biogen To Spin-Off Bioverativ"
8:
626:Biotechnology companies of the United States
178:completed its acquisition on March 8, 2018.
19:
621:Biotechnology companies established in 2016
421:"Shire clinches $ 32bn takeover of Baxalta"
651:American subsidiaries of foreign companies
402:"Sanofi Agrees to Buy Biovia for $ 11.6BN"
18:
366:
364:
611:Companies formerly listed on the Nasdaq
335:
606:American companies established in 2016
318:The company has two current products;
7:
396:
394:
392:
267:
242:
232:
200:Securities and Exchange Commission
14:
438:D'Souza, Savio (May 3, 2016).
419:Farrell, Sean (January 2016).
16:American biotechnology company
1:
641:2018 mergers and acquisitions
203:trading on January 12, 2017.
158:. Bioverativ competes with
667:
65:; 8 years ago
273:
265:
248:
240:
190:announced that it would
406:Pharma Technology Focus
250:True North Therapeutics
212:cold agglutinin disease
208:True North Therapeutics
278:(Spun off 2016 from
631:Corporate spin-offs
225:Acquisition history
108:Number of employees
21:
102:Alprolix, Eloctate
471:. 10 August 2016.
404:. Industry News.
310:
309:
301:
300:
292:
291:
283:
254:
217:In January 2018,
142:
141:
658:
590:
589:
587:
585:
570:
564:
563:
556:
550:
549:
542:
533:
532:
518:
512:
511:
504:
498:
497:
495:
494:
485:. Archived from
479:
473:
472:
461:
455:
454:
452:
450:
435:
429:
428:
416:
410:
409:
398:
387:
386:
384:
382:
368:
359:
358:
356:
355:
346:. Archived from
340:
277:
268:
252:
243:
233:
138:
135:
73:
71:
66:
22:
666:
665:
661:
660:
659:
657:
656:
655:
596:
595:
594:
593:
583:
581:
572:
571:
567:
558:
557:
553:
544:
543:
536:
520:
519:
515:
506:
505:
501:
492:
490:
481:
480:
476:
463:
462:
458:
448:
446:
437:
436:
432:
418:
417:
413:
400:
399:
390:
380:
378:
370:
369:
362:
353:
351:
342:
341:
337:
332:
316:
311:
302:
293:
276:
251:
227:
184:
147:is an American
145:Bioverativ Inc.
132:
109:
94:
86:
75:(Spun off from
74:
69:
67:
64:
39:
20:Bioverativ Inc.
17:
12:
11:
5:
664:
662:
654:
653:
648:
643:
638:
633:
628:
623:
618:
613:
608:
598:
597:
592:
591:
565:
562:. 23 May 2017.
551:
534:
521:Cornell, Joe.
513:
499:
474:
456:
430:
411:
388:
360:
334:
333:
331:
328:
315:
312:
308:
307:
304:
303:
299:
298:
295:
294:
290:
289:
286:
285:
272:
266:
264:
261:
260:
257:
256:
247:
241:
239:
231:
226:
223:
183:
180:
140:
139:
130:
126:
125:
120:
114:
113:
110:
107:
104:
103:
100:
96:
95:
87:
84:
81:
80:
61:
57:
56:
51:
47:
46:
40:
35:
32:
31:
26:
15:
13:
10:
9:
6:
4:
3:
2:
663:
652:
649:
647:
644:
642:
639:
637:
634:
632:
629:
627:
624:
622:
619:
617:
614:
612:
609:
607:
604:
603:
601:
580:
576:
569:
566:
561:
555:
552:
547:
541:
539:
535:
530:
529:
524:
517:
514:
509:
503:
500:
489:on 2016-08-13
488:
484:
478:
475:
470:
469:Fierce Pharma
466:
460:
457:
445:
441:
434:
431:
426:
422:
415:
412:
407:
403:
397:
395:
393:
389:
377:
373:
367:
365:
361:
350:on 2016-12-29
349:
345:
339:
336:
329:
327:
325:
321:
313:
306:
305:
297:
296:
288:
287:
284:
281:
270:
269:
263:
262:
259:
258:
255:
245:
244:
238:
235:
234:
230:
224:
222:
220:
215:
213:
209:
204:
201:
197:
193:
189:
181:
179:
177:
173:
169:
165:
162:(acquired by
161:
157:
153:
152:biotechnology
150:
149:multinational
146:
137:
131:
127:
124:
121:
119:
115:
111:
105:
101:
97:
92:
89:John G. Cox (
88:
82:
78:
62:
58:
55:
54:Biotechnology
52:
48:
44:
41:
38:
33:
30:
27:
23:
582:. Retrieved
578:
568:
554:
526:
516:
502:
491:. Retrieved
487:the original
477:
468:
459:
447:. Retrieved
443:
433:
425:The Guardian
424:
414:
405:
379:. Retrieved
375:
352:. Retrieved
348:the original
338:
317:
274:
249:
236:
228:
216:
205:
195:
186:In May 2016
185:
172:Novo Nordisk
144:
143:
25:Company type
584:February 3,
275:Bioverativ
156:haemophilia
45:: BIVV
600:Categories
493:2016-12-28
354:2016-12-28
330:References
253:(Acq 2017)
237:Bioverativ
196:Bioverativ
166:in 2016),
85:Key people
29:Subsidiary
164:Shire Plc
37:Traded as
372:"Biogen"
324:Eloctate
320:Alprolix
314:Products
192:spin off
99:Products
50:Industry
579:Reuters
444:Reuters
376:SEC.gov
271:
246:
182:History
160:Baxalta
129:Website
68: (
60:Founded
636:Sanofi
528:Forbes
449:May 3,
381:22 May
280:Biogen
219:Sanofi
188:Biogen
176:Sanofi
168:Pfizer
134:sanofi
123:Sanofi
118:Parent
77:Biogen
43:Nasdaq
586:2018
451:2016
383:2024
322:and
170:and
136:.com
70:2016
63:2016
112:400
91:CEO
602::
577:.
537:^
525:.
467:.
442:.
423:.
391:^
374:.
363:^
214:.
588:.
548:.
531:.
510:.
496:.
453:.
427:.
385:.
357:.
282:)
93:)
79:)
72:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.